Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has announced equity grants to newly hired employees. The company granted 86,665 restricted stock units (RSUs) to four new hires, vesting in four equal annual installments. Additionally, one employee received an option to purchase 100,000 shares of common stock at $8.64 per share, vesting over four years. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), serving as inducements for employment.
Solid Biosciences Inc. (Nasdaq: SLDB), un'azienda operante nel settore delle scienze della vita specializzata in medicine genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato concessioni azionarie ai nuovi assunti. L'azienda ha concesso 86.665 unità azionarie riservate (RSU) a quattro nuovi dipendenti, cumulabili in quattro rate annuali uguali. Inoltre, un dipendente ha ricevuto un'opzione per acquistare 100.000 azioni di azioni ordinarie a $8,64 per azione, con maturazione su un periodo di quattro anni. Questi accordi sono stati effettuati nell'ambito del Piano di Incentivi Azionari per Assunzione 2024 dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), fungendo da incentivi per l'occupazione.
Solid Biosciences Inc. (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado otorgamientos de acciones a los nuevos empleados contratados. La empresa otorgó 86,665 unidades de acciones restringidas (RSUs) a cuatro nuevas contrataciones, que se acumularán en cuatro cuotas anuales iguales. Además, un empleado recibió una opción para comprar 100,000 acciones de acciones comunes a $8.64 por acción, con un periodo de consolidación de cuatro años. Estos otorgamientos se realizaron bajo el Plan de Incentivos de Acciones para Contratación 2024 de la empresa, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4), sirviendo como incentivos para el empleo.
솔리드 바이오사이언스(Solid Biosciences Inc.) (Nasdaq: SLDB)는 근육 및 심장 질환을 위한 정밀 유전자 치료에 초점을 맞춘 생명 과학 회사로, 새로 채용된 직원들에게 주식 보상을 발표했습니다. 회사는 네 명의 신규 직원에게 86,665 제한 주식 단위(RSU)를 부여했으며, 이는 4년에 걸쳐 동일한 연간 할부로 분할 지급됩니다. 추가로 한 직원은 100,000주의 보통주를 주당 $8.64에 구매할 수 있는 옵션을 받았으며, 이는 4년에 걸쳐 분할 지급됩니다. 이러한 보상은 회사의 2024 유인 주식 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 의해 고용 유인으로 제공되었습니다.
Solid Biosciences Inc. (Nasdaq: SLDB), une entreprise de sciences de la vie axée sur des médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé des attributions d'actions aux nouveaux employés recrutés. L'entreprise a accordé 86 665 unités d'actions restreintes (RSUs) à quatre nouveaux salariés, qui se débloqueront en quatre versements annuels égaux. De plus, un employé a reçu une option d'achat de 100 000 actions ordinaires au prix de 8,64 $ par action, avec un déblocage sur quatre ans. Ces attributions ont été réalisées dans le cadre du Plan d'incitation par actions pour 2024 de l'entreprise, conformément à la règle d'inscription Nasdaq 5635(c)(4), servant d'incitatifs à l'emploi.
Solid Biosciences Inc. (Nasdaq: SLDB), ein Unternehmen der Life Sciences, das sich auf präzise genetische Medikamente für neuromuskuläre und Herzkrankheiten konzentriert, hat Aktienvergaben an neu eingestellte Mitarbeiter angekündigt. Das Unternehmen hat 86.665 eingeschränkte Aktieneinheiten (RSUs) an vier neue Mitarbeiter vergeben, die in vier gleichen jährlichen Raten fällig werden. Darüber hinaus erhielt ein Mitarbeiter eine Option zum Kauf von 100.000 Aktien zu einem Preis von 8,64 $ pro Aktie, die über einen Zeitraum von vier Jahren fällig wird. Diese Gewährungen erfolgten im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens gemäß der Nasdaq-Listingregel 5635(c)(4) und dienen als Anreiz für die Beschäftigung.
- Attraction of new talent with equity incentives
- Implementation of long-term employee retention strategy through 4-year vesting periods
- Potential dilution of existing shareholders' equity due to new stock grants
CHARLESTOWN, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 86,665 restricted stock units (“RSUs”) to four newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
One newly hired employee also received an option to purchase up to 100,000 shares of the Company’s common stock. The option has a ten-year term and an exercise price of
These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many restricted stock units (RSUs) did Solid Biosciences (SLDB) grant to new employees?
What is the vesting schedule for the RSUs granted by Solid Biosciences (SLDB)?
What stock option was granted to one newly hired employee of Solid Biosciences (SLDB)?
Under which plan were these equity grants made by Solid Biosciences (SLDB)?
